HK Stock Market Move | TRANSTHERA-B (02617) fell more than 11% during trading hours. The company plans to have all H shares traded, accounting for approximately 11.33% of the total issued shares.

TRANSTHERA-B (02617) fell by more than 11% during trading hours, and as of the time of writing, it has fallen by 9.74% to HK$176.2, with a trading volume of HK$5.91 billion. On the news front, Pharmaron Health announced yesterday that the Board of Directors has considered and approved an application to the China Securities Regulatory Commission to convert 44.9711 million shares of domestic shares held by 10 shareholders of the company into H shares, accounting for approximately 11.33% of the total issued shares of the company. After obtaining all relevant approvals and complying with all applicable laws, regulations, and rules, these domestic shares will be converted into H shares and will qualify for listing and trading on the Main Board of the Stock Exchange. It is worth noting that on October 16-17, Pharmaron Health rebounded strongly again, with a cumulative increase of nearly 80% over the two days. In "From HK$679 to HK$112, back to HK$224: Who is "worshipping" TRANSTHERA-B (02617)?" it is pointed out that the violent rebound of Pharmaron Health in this round was initiated by international short-term speculative funds, but was used by mainland main funds as a "selling window". When the largest group of position holders not only does not participate in buying, but instead becomes the largest seller, the foundation of this rebound has been hollowed out, relying entirely on the influx of follow-up capital and short-term funds from international speculative funds.